MOTS-c dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of MOTS-c actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
MOTS-c reconstitution chart
Units on a standard U-100 insulin syringe, where 100 units is 1 mL. The rows are the absolute doses quoted in studies of MOTS-c, from 500 mcg to 500 mcg, so this chart is specific to this compound rather than a generic ladder. More diluent means more units for the same dose, which is easier to measure accurately and empties the vial no faster.
| Dose | 1 mL diluent (2,000 mcg/mL) | 2 mL diluent (1,000 mcg/mL) | 3 mL diluent (667 mcg/mL) |
|---|---|---|---|
| 500 mcg | 25 | 50 | 75 |
| Dose | 1 mL diluent (5,000 mcg/mL) | 2 mL diluent (2,500 mcg/mL) | 3 mL diluent (1,667 mcg/mL) |
|---|---|---|---|
| 500 mcg | 10 | 20 | 30 |
| Dose | 1 mL diluent (10,000 mcg/mL) | 2 mL diluent (5,000 mcg/mL) | 3 mL diluent (3,333 mcg/mL) |
|---|---|---|---|
| 500 mcg | 5 | 10 | 15 |
Read a figure off this chart only if it matches the vial in front of you. A vial labelled a different strength, or reconstituted with a different volume, gives a different number for the same dose, and that is the single most common way these calculations go wrong.
Doses in published studies of MOTS-c
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. None is a human dose: no study here administered MOTS-c to people at a stated dose.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Animal, preclinical | Animal study, mice, 2026: doses stated in the abstract: 15 mg/kg. In vivo , male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle. | pmid-42266945 |
| Animal, preclinical | Animal study, mice, n=6, 2026: doses stated in the abstract: 5 mg/kg. In vivo studies demonstrated that daily intraperitoneal administration of R13A-MOTS-c (5 mg/kg for 2 weeks) effectively mitigated radiation-induced pulmonary inflammation, oxidative stress, and mitochondrial dysfunction in C57BL/6 mice exposed to 20 Gy thoracic… | pmid-42142418 |
| Animal, preclinical | Animal study, rats, 2026: doses stated in the abstract: 0.25-0.7 mg/kg; 0.5 mg. Isolated Langendorff-perfused rat hearts underwent 30-min global ischemia and 60-min reperfusion with or without MOTS-c (0.25-0.7 mg/kg) delivered via Krebs-Henseleit buffer during the first 10 min of reperfusion. | pmid-41593376 |
| Animal, preclinical | Animal study, rats, 2025: doses stated in the abstract: 15 mg/kg. Treated diabetic group received MOTS-c (15 mg/kg) daily injection for 3 weeks. | pmid-40661667 |
| Animal, preclinical | Animal study, mice, 2021: doses stated in the abstract: 500 μg. Long-term repeated administration of MOTS-c (500 μg) and PMO at the dose of 12.5 mg/kg/week for 3 weeks followed by 12.5 mg/kg/month for 3 months (PMO-M) induced therapeutic levels of dystrophin expression in peripheral muscles, with up to 25-fold increase in diaphragm of… | pmid-33337582 |
Weight-normalised doses, and why they are not on the chart
Some studies state a dose per kilogram. Those figures are deliberately absent from the chart above, because multiplying one by a body weight produces a number that looks like a dose and is not one. Interspecies scaling is not arithmetic: a rat milligram-per-kilogram figure does not become a human dose by multiplication.
- Animal study, mice, 2026: weight-normalized doses as published: 15 mg/kg. In vivo , male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle. pmid-42266945
- Animal study, mice, n=6, 2026: weight-normalized doses as published: 5 mg/kg. In vivo studies demonstrated that daily intraperitoneal administration of R13A-MOTS-c (5 mg/kg for 2 weeks) effectively mitigated radiation-induced pulmonary inflammation, oxidative stress, and mitochondrial dysfunction in C57BL/6 mice exposed to 20 Gy… pmid-42142418
- Animal study, rats, 2026: weight-normalized doses as published: 0.25-0.7 mg/kg. Isolated Langendorff-perfused rat hearts underwent 30-min global ischemia and 60-min reperfusion with or without MOTS-c (0.25-0.7 mg/kg) delivered via Krebs-Henseleit buffer during the first 10 min of reperfusion. pmid-41593376
- Animal study, rats, 2025: weight-normalized doses as published: 15 mg/kg. Treated diabetic group received MOTS-c (15 mg/kg) daily injection for 3 weeks. pmid-40661667
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of MOTS-c actually ran for.
- Randomized controlled trial, humans, 2022: durations stated: 24 weeks. We failed to find any significant alteration of circulating MOTS-c -as measured using the commercially available competitive ELISA CEX132Hu- in response to 24 weeks of a neoadjuvant chemotherapy/trastuzumab regimen with or without daily metformin. pmid-36490309
- Animal study, mice, n=6, 2026: durations stated: 2 weeks. In vivo studies demonstrated that daily intraperitoneal administration of R13A-MOTS-c (5 mg/kg for 2 weeks) effectively mitigated radiation-induced pulmonary inflammation, oxidative stress, and mitochondrial dysfunction in C57BL/6 mice exposed to 20 Gy thoracic irradiation. pmid-42142418
- Animal study, rats, 2025: durations stated: 7 day. After the end of the experiment, we conducted an ex vivo fatigue test of soleus muscle and showed that the MOTS-c administration prevents increased fatigue during 7-day hind limb unloading. pmid-40608240
- Animal study, rats, 2025: durations stated: 3 weeks. Treated diabetic group received MOTS-c (15 mg/kg) daily injection for 3 weeks. pmid-40661667
- Animal study, mice, 2021: durations stated: 3 weeks; 3 months. Long-term repeated administration of MOTS-c (500 μg) and PMO at the dose of 12.5 mg/kg/week for 3 weeks followed by 12.5 mg/kg/month for 3 months (PMO-M) induced therapeutic levels of dystrophin expression in peripheral muscles, with up to 25-fold increase in diaphragm of… pmid-33337582
Storage and stability, as published
Reconstitution starts a clock. These are the storage and stability conditions stated in papers in this ledger. They describe what the study did, which is not the same as a shelf life for a vial in your fridge.
- Animal study, rats, 2025: Thus, the MOTS-C injections during hind limb unloading lead to the normalization of several protein synthesis and degradation processes and support the expression of genes that ensure muscle resistance to fatigue. pmid-40608240
How MOTS-c was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Human study, humans, 2024: administration by intravenous route reported. Notably, MOTS-c protein expression declined with ACC progression (stages III and IV) but was unrelated to patient age or sex. pmid-39201408
- Animal study, mice, 2026: administration by intraperitoneal route reported. In vivo , male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle. pmid-42266945
- Animal study, mice, n=6, 2026: administration by intraperitoneal route reported. In vivo studies demonstrated that daily intraperitoneal administration of R13A-MOTS-c (5 mg/kg for 2 weeks) effectively mitigated radiation-induced pulmonary inflammation, oxidative stress, and mitochondrial dysfunction in C57BL/6 mice exposed to 20 Gy… pmid-42142418
- Animal study, rats, n=16, 2026: administration by subcutaneous route reported. Adult male Wistar rats (n = 16) received continuous MOTS-c (0.1 μmol/24 h) or saline via subcutaneous micro-osmotic pumps for 24 hours. pmid-41811086
- Animal study, rats, 2026: administration by intraperitoneal route reported. Female and male offspring were treated with 0.5 mg/kg/day MOTS-c or saline intraperitoneally from postnatal days 21 to 46. pmid-41706383
- Animal study, mice, n=6, 2026: administration by intraperitoneal route reported. Administration of MOTS-c via i.p. injection markedly attenuated APAP-induced increases in AST and ALT levels, histopathological liver damage, and other liver injury markers. pmid-41764620
Questions people ask
- How many units is 500 mcg of MOTS-c?
- It depends entirely on how the vial was reconstituted. In a 5 mg vial with 2 mL of diluent it is 20 units on a U-100 syringe; with 1 mL it is 10. The chart above gives the rest.
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the MOTS-c record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. For MOTS-c there is no human dose in this ledger to copy even if you wanted one.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures